Rhaponticin (Stilbene Glucoside · Menopausal Support · Phytoestrogenic)
| Compound | Rhaponticin |
| Chemical class | Polyphenol — Stilbene Glucoside (Rhapontigenin-3-O-glucoside) |
| CAS | 155-58-8 |
| Primary source | Rheum rhaponticum, Rheum emodi (rhubarb rhizome) |
| Key applications | Phytoestrogenic, metabolic, anti-inflammatory |
| Claim strength | Moderate |
| Typical form | Rhubarb rhizome extract; rhaponticin isolate |
| Buy from Herbuno |
India Rhubarb Liquid Extract (Water Soluble) - Rheum emodi → India Rhubarb Oil Soluble Extract - Rheum emodi → |
Name origin: From Rhaponticum — the historical genus name for the Pontic rhubarb species (Rheum rhaponticum). Rhaponticin is the 3-O-glucoside of rhapontigenin, a stilbene closely related to resveratrol with a 4′-methoxy group replacing one hydroxyl. Traditional use: Rhubarb root (Da Huang, Rheum spp.) has extensive use in TCM and Ayurveda for digestive complaints, constipation, and gynaecological conditions. The anthraquinone fraction (emodin, aloe-emodin) is responsible for laxative activity; rhaponticin is a separate stilbene fraction with distinct phytoestrogenic and metabolic activities. Research trajectory: Rhaponticin has attracted research as the primary active in Rheum rhaponticum root extract (ERr 731, a standardised menopause supplement with multiple RCTs). It has ERβ agonist activity and documented effects on menopausal symptoms, metabolic syndrome, and inflammatory pathways. Commercial source: Commercially available via rhubarb root extract. See sourcing options below.
Evidence for Rhaponticin Applications
Menopausal symptom relief: ERr 731 (a standardised Rheum rhaponticum root extract delivering rhaponticin as the primary active) has been evaluated in multiple European RCTs, demonstrating significant reduction in hot flush frequency and severity, improved sleep, and reduced anxiety in periand postmenopausal women. A systematic review confirms clinically meaningful hot flush reduction comparable to low-dose HRT. Claim strength: Moderate (well-designed RCTs for the standardised extract; rhaponticin-specific attribution strong within ERr 731 framework).
Metabolic and anti-adipogenic: Rhaponticin activates AMPK and reduces adipocyte differentiation in cell models. Animal studies show improved insulin sensitivity and reduced visceral adiposity. Mechanistic overlap with resveratrol (via the stilbene scaffold) is proposed. Claim strength: Moderate.
Anti-inflammatory: Rhaponticin inhibits NF-κB and COX-2 in macrophage models, with anti-inflammatory activity comparable to resveratrol analogues. The glucoside form has different pharmacokinetics from the aglycone rhapontigenin; gut microbial hydrolysis is required for aglycone absorption. Claim strength: Moderate.
India Rhubarb Liquid Extract (Water Soluble) - Rheum emodi →
India Rhubarb Oil Soluble Extract - Rheum emodi →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
ERr 731 menopausal RCTs: 4 mg/day rhaponticin (as ERr 731 standardised Rheum rhaponticum root extract). This is an exceptionally low absolute dose reflecting rhaponticin’s high ERβ affinity. For rhubarb root extract preparations not standardised to ERr 731 specifications, rhaponticin content must be HPLC-verified to enable dose calculation relative to the clinical evidence.
Note: rhubarb root extracts also contain anthraquinones (emodin, rhein) which have laxative activity at higher doses. For menopausal or metabolic formulations (not targeting laxative effects), low-anthraquinone or anthraquinone-reduced rhubarb stilbene extracts should be specified. Herbuno’s India Rhubarb extracts should be assessed for anthraquinone content alongside rhaponticin before formulation use.
Rhaponticin as a glucoside is water-soluble; the aglycone rhapontigenin has lower aqueous solubility. Standard capsule/tablet formats are appropriate. Stability at neutral pH is good; avoid prolonged exposure to alkaline conditions which may hydrolyse the glucoside.
Frequently Asked Questions — Rhaponticin
What is ERr 731 and how does it relate to rhaponticin?
ERr 731 is a proprietary standardised Rheum rhaponticum root extract (developed by Schaper & Brümmer) standardised to rhaponticin content as the primary biomarker. Multiple European RCTs have demonstrated its menopausal efficacy. Rhaponticin is the stilbene glucoside identified as the primary phytoestrogenic active. Formulations seeking to reference ERr 731 clinical evidence should use the proprietary extract or demonstrate equivalence in rhaponticin content and botanical identity.
Is rhubarb extract safe for long-term use given its anthraquinone content?
High-dose anthraquinone-containing rhubarb preparations have laxative effects and long-term stimulant laxative use has regulatory concern in many markets. For menopausal or metabolic supplement applications, low-dose rhubarb stilbene extracts with low or absent anthraquinone content are required. ERr 731 is specifically low in anthraquinones by design. Formulators must specify anthraquinone limits (typically <10 ppm emodin + rhein) in procurement specifications.
Is rhaponticin a safer phytoestrogen than genistein for hormone-sensitive populations?
Rhaponticin has ERβ selectivity and lower ERα affinity compared to genistein. ERβ-selective phytoestrogens are theoretically preferable for hormone-sensitive populations as ERα drives most oestrogen-dependent cancer cell proliferation. However, clinical safety data for rhaponticin in ER-positive breast cancer history specifically are not available. The same precautionary advisory framework as for other phytoestrogens applies.
Can rhaponticin be positioned alongside soy isoflavones for menopausal support?
Yes. Rhaponticin (ERβ agonist, stilbene class) and genistein/daidzein (ERβ agonist, isoflavone class) have overlapping menopausal mechanisms through different botanical sources and chemical scaffolds. Co-formulation provides botanical diversity and dual-mechanism phytoestrogenic coverage. Dose management is important — both contribute to total phytoestrogenic load and combined estrogenic exposure should be estimated when designing the formulation.
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery